Skip to main content

Table 4 Association of clinical, pathological and genotypic parameters with progression free survival (PFS).

From: A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

Parameters n Events %PFS p
Tumor size     
   T2 76 12 62.6 0.089
   T3-T4 19 6 59.3  
Lymph node involvement     
   N0 76 10 57.31 0.0011
   N1-N2 19 8 44.7  
Stage     
   IIa 65 8 58.2 0.0232
   IIb 20 6 65.1  
   IIIa-IIIb 10 4 42.3  
RR4M     
   Responders 35 1 96.7 0.0033
   Non-responders 60 17 45.6  
rs10046     
   GG 18 3 80.0 0.967
   AG/AA 80 15 81.3  
rs4646     
   CC 57 7 85.7 0.0686
   AC/AA 38 11 50.9